22218-55-9Relevant articles and documents
Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors
Yahiaoui, Samir,Pouget, Christelle,Fagnere, Catherine,Champavier, Yves,Habrioux, Gérard,José Chulia, Albert
, p. 5215 - 5218 (2004)
Aromatase is a target of pharmaceutical interest for the treatment of estrogen-dependent cancers. Azole derivatives such as letrozole or anastrozole have been developed for aromatase inhibition and are used for the treatment of breast tumors. In this paper, four 4-triazolylflavans were synthesized and were found to exhibit moderate to high inhibitory potency against aromatase.
Design, synthesis and evaluation of 4-imidazolylflavans as new leads for aromatase inhibition
Pouget, Christelle,Fagnere, Catherine,Basly, Jean-Philippe,Habrioux, Gerard,Chulia, Albert Jose
, p. 2859 - 2861 (2007/10/03)
Two 4-imidazolylflavans were synthesized and their relative stereochemistry was established by 1H and 13C NMR data. These compounds were tested for their activity to inhibit aromatase. It was observed that the introduction of an imidazolyl group at carbon 4 on flavan nucleus led to potent molecules.
Synthesis and structure of flavan-4-ols and 4-methoxyflavans as new potential anticancer drugs
Pouget, Christelle,Fagnere, Catherine,Basly, Jean-Philippe,Leveque, Hubert,Chulia, Albert-José
, p. 6047 - 6052 (2007/10/03)
Reduction of a series of substituted flavanones afforded synthetic access to flavan-4-ols and was followed for some of them by an S(N)2-type acid-catalysis in methanol to provide 4-methoxyflavans. The stereochemistry of these compounds was established by 1H and 13C NMR data. Flavan-4-ols and 4-methoxyflavans have been resolved into enantiomers which are being evaluated as anticancer drugs. (C) 2000 Elsevier Science Ltd.